Poll: In an RCC patient with a 4- to 7-cm tumor and no metastasis, which one of the following treatments would you recommend?

A comprehensive guide to the key regulatory decisions and conferences slated for Q3 of 2025.

Data from the #HOPE4KIDNEY trial is intended to support submission for regulatory clearance of the Edison Histotripsy System.

The new drug application is backed by data from the phase 2/3 FRUSICA-2 trial.

ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.

The approvals are supported by findings from the phase 3 CheckMate-67T trial.